Identification of SUMO Targets Associated With the Pluripotent State in Human Stem Cells

Authors
Barbara Mojsa, Michael H. Tatham, Lindsay Davidson, Magda Liczmanska, Emma Branigan, and Ronald T. Hay

Correspondence
r.t.hay@dundee.ac.uk

In Brief
The role of SUMO modification in maintenance of human induced pluripotent stem cells was investigated using an inhibitor of SUMO modification. Key markers of pluripotency were lost after inhibitor treatment. Employing SUMO site proteomics, we identified 976 sites in 427 proteins. A major network of zinc-finger transcription factors linked to TRIM28 was associated with silencing of retroviral elements. At the site level there appears to be a preference for SUMO2 modification over SUMO1 in acidic domains.

Highlights
• SUMO inhibition in human stem cells reduced pluripotency markers.
• SUMO site proteomics identified 976 SUMO sites in 427 proteins.
• SUMO targets functioned in gene expression, ribosome biogenesis, and RNA splicing.
• There is a preference for SUMO2 over SUMO1 modification in acidic domains.

https://doi.org/10.1016/j.mcpro.2021.100164
Identification of SUMO Targets Associated With the Pluripotent State in Human Stem Cells

Barbara Mojsa¹, Michael H. Tatham¹, Lindsay Davidson², Magda Liczmanska¹, Emma Branigan¹, and Ronald T. Hay¹,*

To investigate the role of SUMO modification in the maintenance of pluripotent stem cells, we used ML792, a potent and selective inhibitor of SUMO Activating Enzyme. Treatment of human induced pluripotent stem cells with ML792 resulted in the loss of key pluripotency markers. To identify putative effector proteins and establish sites of SUMO modification, cells were engineered to stably express either SUMO1 or SUMO2 with C-terminal TGK to KGG mutations that facilitate GlyGly-K peptide immunoprecipitation and identification. A total of 976 SUMO sites were identified in 427 proteins. STRING enrichment created three networks of proteins with functions in regulation of gene expression, ribosome biogenesis, and RNA splicing, although the latter two categories represented only 5% of the total GGK peptide intensity. The rest have roles in transcription and the regulation of chromatin structure. Many of the most heavily SUMOylated proteins form a network of zinc-finger transcription factors centered on TRIM28 and associated with silencing of retroviral elements. At the level of whole proteins, there was only limited evidence for SUMO paralogue-specific modification, although at the site level there appears to be a preference for SUMO2 modification over SUMO1 in acidic domains. We show that SUMO influences the pluripotent state in hiPSCs and identify many chromatin-associated proteins as bona fide SUMO substrates in human induced pluripotent stem cells.

Pluripotent cells display the property of self-renewal and have the capacity to generate all of the different cells required for the development of the adult organism. The pluripotent state is defined by a specific gene expression program driven by expression of the core transcription factors OCT4, SOX2, and NANOG that sustain their own expression by virtue of a positive, linked autoregulatory loop, while activating genes required to maintain the pluripotent state and repressing expression of the transcription factors for lineage-specific differentiation (1). Once terminally differentiated, somatic cell states are remarkably stable; however, forced expression of key pluripotency transcription factors that are highly expressed in embryonic stem cells (ESCs), including OCT4, SOX2, and NANOG, leads to reprogramming back to the pluripotent state (2–4). Under normal circumstances, the efficiency of reprogramming is very low, and it is clear that there are roadblocks to reprogramming designed to safeguard cell fates (5, 6). The Small Ubiquitin-like Modifier (SUMO) has emerged as one such roadblock and reduced SUMO expression decreases the time taken and increases the efficiency of reprogramming in mouse cells (7–9). Three SUMO paralogues, known as SUMO1, SUMO2, and SUMO3, are expressed in vertebrates. Based on almost indistinguishable functional and structural features SUMO2 and SUMO3 are collectively termed SUMO2/3 and share about 50% amino acid sequence identity with SUMO1. SUMO proteomics studies have revealed very high numbers of cellular SUMO substrates (see (10) for a review) and as a consequence, SUMO can influence a wide range of biological processes. However, the proportion of the total cellular pool of a protein that is SUMOylated varies greatly. There are rare examples of almost constitutively SUMOylated proteins such as the Ran GTPase RanGAP1 (11), although the majority of substrates have such low modification stoichiometry that identification from purified SUMO conjugates using Immunoblotting is close to the detection limit (for review see (12)). Conjugation of SUMO to protein substrates is mechanistically similar to that of ubiquitin conjugation but is carried out by a completely separate enzymatic pathway. SUMOs are initially translated as inactive precursors that require a precise proteolytic cleavage, carried out by a set of SUMO-specific proteases (SENPα), to expose the terminal carboxyl group of a Gly-Gly sequence that ultimately forms an isopeptide bond with the ε-amino group of a lysine residue in the modified protein. The heterodimeric E1 SUMO Activating Enzyme (SAE1/SAE2) uses ATP to adenylate the C-terminus of SUMO, before forming a thioester with a cysteine residue in a second active site of the enzyme and releasing AMP. SUMO then undergoes a trans-esterification reaction on to a cysteine residue in the only E2 SUMO conjugating enzyme Ubc9. Assisted by a small group

From the ¹Division of Gene Regulation and Expression and ²Division of Cell and Developmental Biology, School of Life Sciences, University of Dundee, Dundee, UK
*For correspondence: Ronald T. Hay, r.t.hay@dundee.ac.uk.
SUMO Targets in Human Induced Pluripotent Stem Cells

of E3 SUMO ligases, including the PIAS proteins, RanBP2, and ZNF451, the SUMO is transferred directly from Ubc9 onto target proteins (13). Modification of target proteins may be short-lived, with SUMO being removed by a group of SENPs. Together this creates a highly dynamic SUMO cycle where the net SUMO modification status of proteins is determined by the rates of SUMO conjugation and deconjugation (12). Preferred sites of SUMO modification conform to the consensus ψKxE, where ψ represents a large hydrophobic residue (14, 15). A conjugation consensus is present in the N-terminal sequence of SUMO2 and SUMO3 and thus permits self-modification and the formation of SUMO2/3 chains (16). As a strict consensus is absent from SUMO1, it does not form chains as readily as SUMO2/3 (12). Once linked to target proteins, SUMO allows the formation of new protein–protein interactions as the modification can be recognized by proteins containing a short stretch of hydrophobic amino acids termed a SUMO interaction motif (17).

Stem cell lines are an excellent model to study the mechanisms that control self-renewal and pluripotency. Mouse ESCs have been widely used for these studies as the cells can also be used in mice for in vivo applications. However, they display different characteristics from human ESCs. Mouse ESCs require leukemia inhibitory factor (LIF) and bone morphogenetic protein (BMP) signaling to maintain their self-renewal and pluripotency (18, 19). In contrast, LIF does not support self-renewal and BMPs induce differentiation in human ESCs (20–22). The maintenance of the pluripotent state of hESCs requires basic fibroblast growth factor (bFGF, FGF2) and activin/nodal/TGF-β signaling along with inhibition of BMP signaling (23, 24). These differences may reflect the particular developmental stages at which ESC lines are established in vitro from mouse and human blastocysts or may be due to differences in early embryonic development (25). As hESCs are derived from embryos, their use is limited, but human induced pluripotent stem cells (hiPSC) can be derived by reprogramming normal somatic cells and display most of the characteristics of hESCs (2) and are now widely used to study self-renewal and pluripotency in humans.

To determine the role of SUMO modification in hiPSCs, we made use of ML792, a highly potent and selective inhibitor of the SUMO Activating Enzyme (26). Treatment of hiPSCs with this inhibitor rapidly blocks SUMO modification allowing endogenous SUMO proteases to strip SUMO from targets. When used over the course of 48 h, hiPSCs treated with ML792 lose the majority of SUMO conjugation but show no large-scale changes to the cellular proteome nor loss of viability, although markers of pluripotency are reduced. Decreased expression of selected pluripotency markers seems to be a consequence of SUMO removal from key targets rather than extensive changes to the proteome. SUMO site proteomic analysis of hiPSCs reveals extensive SUMO modification of proteins involved in transcriptional repression, RNA splicing, and ribosome biogenesis. At the protein level most proteins do not appear to display SUMO paralogue-specific modification, while at the level there is clear evidence of SUMO paralogue specificity. This site-specific selectivity appears, at least in part, to be influenced by proximal amino acids, with generally acidic domains being preferentially modified by SUMO2.

**EXPERIMENTAL PROCEDURES**

**Antibodies and Inhibitors**

Rabbit antibodies against TRIM28 (4124S, 4123S), CTCF (3418S), OCT4A (2890S), SOX2 (23064S), NANO2 (3580S), KLF4 (12173S), SUMO2 (4971S), and mouse antibodies against TRA-1-60 (4746T), TRA-1-81 (4745T), SSEA-4 (475T), and SMA (D4K9N) were from Cell Signalling Technology. Anti-SALL4 (ab29112), anti-TRIM24 (ab70560), anti-NOP58 (ab155556), anti-NESTIN (ab196908) were from Abcam. Mouse antibody against α-Tubulin was from Bethyl Laboratories, mouse anti-LaminA/C antibody was from Sigma Aldrich (SAB4200236), rabbit anti-mCherry (PA5-34974), rabbit anti-TRIM33 (PA5-82152) were from Invitrogen, and mouse anti-HIS (34650) was from Qiagen. Rabbit anti-CYTOKERATIN17 was a gift from R. Hickerson (University of Dundee). Sheep antibodies against SUMO1, SUMO2 (27) were generated in-house. Secondary antibodies conjugated with HRP and Alexa fluorophores, Cy3 Cellmask (C10045), Rhodamine Phalloidin (R415) were from Sigma and Invitrogen, respectively. ML792 (1644324-14-2), MG132 (474787), and N-ethylmaleimide (E3876) were from Sigma Aldrich. Protease Inhibitor cocktail (11836170001) was from Roche. Propidium iodide (P3566) and DAPI (D1306) were from Life Technologies.

**Cloning**

SUMO1-KGG-mCherry and SUMO2-KGG-mCherry PiggyBac expression vectors were generated by Gateway cloning. Briefly, SUMO1, SUMO2, and mCherry fragments were PCR amplified using the following resources: 6His SUMO1 T95K (300 nt) from pSCAI88 and 6His SUMO2 T90K (300 nt) from pSCAI89 with a common forwards primer (5′-CACCatgcatcatatcatatcatgtc-3′) and set of specific mCherry fusing primers (5′-TCACATATACCCCATTTGGTCTCAG-3′ and 5′-TCACATATACCCCATTTGGTCTCAG-3′) in-house. Secondary antibodies conjugated with HRP and Alexa fluorophores, Cy3 Cellmask (C10045), Rhodamine Phalloidin (R415) were from Sigma and Invitrogen, respectively. ML792 (1644324-14-2), MG132 (474787), and N-ethylmaleimide (E3876) were from Sigma Aldrich. Protease Inhibitor cocktail (11836170001) was from Roche. Propidium iodide (P3566) and DAPI (D1306) were from Life Technologies.

Human ESC lines (SA121 and SA181) were obtained from Cellartis/Takara Bio Europe. All work with hESCs was approved by the UK Stem cell bank steering committee (Approval reference: SCS17-14). Human iPSC lines were obtained from Cellartis/Takara Bio Europe (ChiPS4) or the HiPSC consortium (bubh3, oaqd3, u0ah1, and wibj2). Cell lines were maintained in TESR medium (28) containing FGF2 (Peprotech, 30 ng/ml) and noggin (Peprotech, 10 ng/ml) on growth factor reduced geltrex basement membrane extract (Life Technologies, 10 μg/cm²) coated dishes at 37 °C in a humidified atmosphere of
5% CO2 in air. Cells were routinely passaged twice a week as single cells using TrypLE select (Life Technologies) and replated in TESR medium that was further supplemented with the Rh kinase inhibitor Y27632 (Tocris, 10 μM). Twenty-four hours after replating, Y27632 was removed from the culture medium. To make SUMO1-KGG-mCherry and SUMO2-KGG-mCherry expressing stable cell lines, ChiPS4 cells were transfected using a Neon electroporation system (Thermo Fisher Scientific) with 10 μl tips. Briefly, ChiPS4 cells were dispersed to single cells as described above, then 1 x 10^6 cells was collected by centrifugation at 300 g for 2 min and resuspended in 11 μl of electroporation buffer R containing 1 μg of either paPX1-SUMO1-KGG-mCherry or paPX1-SUMO2-KGG-mCherry PiggyBac expression vectors along with 0.2 μg of Super PiggyBac transposase (System Biosciences). Electroporation was performed at 1150 V, 1 pulse, 30 ms, and cells plated in mTESR containing Y27632. Five days after electroporation, mCherry positive cells were positively selected by fluorescence-activated cell sorting (FACS) using an SH800 cell sorter (Sony). Monoclonal cell lines were prepared from the bulk sorted population by plating at low density on geltrix-coated dishes and individual clones picked using 3.2 mm cloning discs (Sigma Aldrich) soaked in TrypLE select. Cell lines were then expanded and analyzed to check for expression of mCherry and His-SUMO1/2. Cell viability following ML792 treatment was analyzed using Alamar Blue HS reagent (Invitrogen) according to manufacturer’s instruction.

**Flow Cytometry for Cell Cycle Assessment and Pluripotency Markers**

For cell cycle analysis and staining for pluripotency markers, ChiPS4 cells were harvested using standard procedures, washed and fixed with ice cold 70% ethanol or 4% PFA for the analysis of cell cycle or NANOG staining, respectively. Next cells were stained with propidium iodide or anti-NANOG primary antibody, followed by Alexa 488-conjugated secondary antibody and analyzed by flow cytometry using a Canto analyzer (Becton Dickson). Data was then analyzed using FlowJo 10.

**Immunofluorescence, Cell Painting Assay, and High Content Microscopy**

For IF assays, ChiPS4 cells were seeded on μ-Slide 8-well (Ibidi) or 96-well plates suitable for High Content Microscopy (Nunc). Standard IF procedure was used where appropriate. Briefly, following treatments, cells were washed with PBS, fixed with 4% formaldehyde, blocked in 5% BSA in PBS-T, and incubated with primary followed by Alexa-conjugated secondary antibodies. Cell Painting was performed as described by Bray et al. (23). Imaging and subsequent analysis were performed using IN Cell Analyzer systems (GE Healthcare) and Spotfire (Tibco). Main measures extracted from the Cell Painting assay data set are: area of nuclei (μm²) calculated as a number of pixels in nucleus, multiplied by the area per pixel; nuclei form factor calculated as 4*pi*Area/Perimeter² is a measure of circularity (values between 0 and 1 for a perfectly circular object); nuclei: FITC texture correlation is a measure of relative roughness of the image within the nucleus correlating to the nucleolar staining.

**Protein Sample Preparation and Western Blotting (WB)**

ChiPS4 was maintained in a stable culture as described before and treated with inhibitors for a stated time and dose, usually 400 nM ML792 was used for 24 h or 48 h. For WB, cells were washed with PBS +/- and directly lysed in an appropriate volume of 2x Laemmli buffer (approximately 200 μl of buffer was used per 0.5 x 10⁶ cells) (LD: [4% SDS; 20% Glycerol; 120 mM 1 Tris-Cl (pH 6.8); 0.02% w/v bromophenol blue]) and subsequently sonicated using Bioruptor Twin (Diagenode). Protein content was assessed using BCA Protein Assay (Thermo Fisher Scientific) and for most purposes 15 μg of total protein was loaded per lane on SDS-PAGE gel (NuPage 4–12% polyacrylamide, Bis-Tris with MOPS buffer). Proteins were transferred to PVDF membrane using iBlot 2 Gel Transfer Device (Invitrogen). Membranes were blocked for 1 h in 5% milk in TBS-T and incubated overnight with primary antibodies and 1 h with secondary HRP-conjugated antibodies before being developed using enhanced chemiluminescence (Thermo Fisher Scientific) and exposed to film.

**NINTA Purification**

Cells were washed with PBS and scraped in PBS containing 1 mM N-ethylmaleimide. The cells were then collected by centrifugation at 300 g for 5 min and the pellets weighed. An aliquot of the cells was lysed in 1.2x NuPage sample buffer (Thermo Fisher Scientific) for analysis by Western blotting. The remaining cell pellets (approximately 2 g) were lysed with 5x the pellet weight of lysis buffer (6 M guanidine-HCl, 100 mM sodium phosphate buffer (pH 8.0), 10 mM Tris-HCl (pH 8.0), 10 mM imidazole, and 5 mM 2-mercaptoethanol). DNA was sheared by sonication using a probe sonicator (3 min, 35% amplitude, 20 s pulses, 20 s intervals on ice, and the samples centrifuged at 4000 rpm for 15 min at 4 °C to remove insoluble material). The protein concentration of the lysate was determined using BCA assay, and 6.5 μg of total protein from each sample was then incubated overnight at 4 °C with 50 μl of packed pre-equilibrated Ni-NTA agarose beads. After the overnight incubation, the supernatant was removed and the beads were washed once with ten resin volumes of lysis buffer, followed by one wash with ten resin volumes of 8 M urea, 100 mM sodium phosphate buffer (pH 8.0), 10 mM Tris-HCl (pH 8.0), 10 mM imidazole, and 5 mM 2-mercaptoethanol, and then six washes with ten resin volumes of 8 M urea, 100 mM sodium phosphate buffer (pH 6.3), 10 mM Tris-HCl (pH 8.0), 10 mM imidazole, and 5 mM 2-mercaptoethanol. Proteins were eluted from Ni-NTA agarose beads with 125 μl 1.2x NuPAGE sample buffer for SDS-PAGE.

**Mass-spectrometry-based Proteomics and Quantitative Data Analysis**

Three proteomic experiments are described in this study; (1) Changes in total proteome of ChiPS4 cells during ML792 treatment ChiPS4 cells were either DMSO treated (0 h condition) or treated with 400 nM ML792 for 24 h or 48 h. Four replicates of each condition were prepared. Crude cell extracts were made to a protein concentration of between 1 and 2 mg/ml by addition of 1.2x NuPAGE sample buffer to PBS washed cells followed by sonication. For each replicate 25 μg protein was fractionated by SDS-PAGE (NuPage 10% polyacrylamide, Bis-Tris with MOPS buffer—Invitrogen) and stained with Coomassie blue. Each lane was excised into four roughly equally sized slices and peptides were extracted by tryptic digestion (30) including alkylation with chloroacetamide. Peptides were resuspended in 35 μl 0.1% TFA 0.5% acetic acid, and 10 μl of each analyzed by LC-MS/MS. This was performed using a Q Exactive mass spectrometer (Thermo Fisher Scientific) coupled to an EASY-nLC 1000 liquid chromatography system (Thermo Fisher Scientific), using an EASY-Spray ion source (Thermo Fisher Scientific) running a 75 μm x 500 mm EASY-Spray column at 45 °C. A 240 min elution gradient with a top ten data-dependent method was applied. Full scan spectra (m/z 300–1800) were acquired with resolution R = 70,000 at m/z 200 (after accumulation to a target value of 1,000,000 ions with maximum injection time of 20 ms). The ten most intense ions were fragmented by HCD and measured with a resolution of R = 17,500 at m/z 200 (target value of 500,000 ions and maximum injection time of 60 ms) and intensity threshold of 2.1 x 10⁵. Peptide match was set to “preferred,” a 40 s dynamic exclusion list was applied, and ions were ignored if they had unassigned charge state 1, 8, or >8. Data analysis used
MaxQuant version 1.6.1.0 (31) with the built-in Andromeda search engine (32). Default settings were used except the match between runs option was enabled, which matched identified peaks among slices from the same position in the gel as well as one slice higher or lower. The uniprot human proteome database (9606-Homo sapiens−downloaded 24/02/2015 - 73920 entries) digested with Trypsin/P (up to three missed cleavages, C-terminal to K and R but not before P) was used as search space. Carbamidomethyl (C) was a fixed modification and variable modifications of Oxidation (M), Acetylation (Protein N-term), GlyGly (K), and Phospho (ST) were also included. Peptide mass tolerances were 20 ppm and 4.5 ppm for first and second searches. 1% false discovery rate filtering was applied at both peptide and protein levels. No minimum Andromeda score was required for the unmodified proteins, but a score of 40 was required for modifications. LFQ intensities were required for each slice but LFQ normalization was switched off. Manual LFQ normalization was done by calculating the relative LFQ intensity compared with average LFQ intensity for each protein found in the same slice across all 12 samples. For each peptide sample, this gave a list of sample LFQ/average LFQ values from which the median was used to normalize all protein LFQ intensities in that sample. The final protein LFQ intensity per lane (and therefore protein sample) was calculated by the sum of normalized values (default settings) and outliers were de

file, and the latter used the peptides.txt file to monitor differences in abundance of SUMO-specific peptides between samples, to infer overexpression levels. For the whole cell protein abundance analysis, only proteins with data in all three replicates of at least one condition were carried forward. In Perseus, zero intensity values were replaced from log2-transformed data (default settings) and outliers were defined by 5% FDR from Student’s t test using an S0 value of 0.1. A summary of these data can be found in supplemental File S2.

(3) Identification of SUMO1 and SUMO2 modified proteins from ChiPS4 cells.

Two repeats of this experiment were performed using approximately 0.5 × 10^6 cells of ChiPS4-6HisSUMO1-KGG-mCherry and ChiPS4-6HisSUMO2-KGG-mCherry per replicate. Protein or peptide samples were taken at different steps of the protocol to assess different fractions. These were: whole cell extracts (WCE), NINTA column elutions (6His), and GlyGly-K immunoprecipitations (GGK). The last being the source of SUMO-substrate branched peptides. The whole procedure was carried out as described previously (34). In brief, crude cell lysates were prepared which approximately 100 μg was retained for whole proteome analysis as described for the two proteomics experiments above. The remaining lysate (~20 mg protein) was used for NINTA chromatic enrichment of 6His-SUMO conjugates. Elutions from the NINTA columns were digested consecutively with LysC then GluC, of which 7% of each was retained for proteomics analysis (6His-SUMO fractions) and the remainder for GlyGly-K immunoprecipitation. The final enriched fractions of LysC and LysC/GluC GG-K peptides were resuspended in a volume of 20 μl for mass spectrometry analysis. Peptides from whole cell extracts were analyzed once by LC-MS/MS using the same system and settings as described for the above experiments except a 180 min gradient was used with a top 12 data-dependent method. NINTA elution peptides were analyzed identically except a 90 min gradient was analyzed using a top five data-dependent method with a maximum MS/MS fill time was increased to 120 ms. GG-K immunoprecipitated peptides were analyzed twice. Firstly, 4 μl was fractionated over a 90 min gradient and analyzed using a top five data-dependent method with a maximum MS/MS fill time of 200 ms. Secondly, 11 μl of sample was fractionated over a 150 min gradient and analyzed using a top three method with a maximum MS/MS injection time of 500 ms. Data from WCE and NINTA elutions were processed together in MaxQuant using Trypsin/P enzyme specificity (two missed cleavages) for WCE samples and LysC (cleaving C-terminal to K and R) with two missed cleavages, or LysC+GluC D/E (considering cleavage after D or E) with six missed cleavages for NINTA elutions. In addition to Oxidation (M) and Acetyl (Protein N-term), phospho (ST) modification was selected for peptides derived from whole cell extract and 6His-SUMO2 fractions. For GGK peptides, the additional PTM of GG-K was included in searches. LysC enzyme was selected with three missed cleavages, or LysC+GluC D/E allowing eight missed cleavages. The human database and sequences of the two exogenous 6His-SUMO-KGG-mCherry constructs described above were used as search space. In all cases every raw file was treated as a separate “experiment” in the design template such that protein or peptide intensities in each sample were reported, allowing for manual normalization where appropriate. Matching between runs was allowed but only for peptide samples from the same cellular fraction (WCE, 6His or GGK), the same or adjacent gel slice (WCE), the same protease (6His and GGK), and the same LC elution gradient. For example, spectra from adjacent gel slices in the WCE fraction across all lanes were matched, and spectra from all GG-K IPs that were digested by the same enzymes were matched. Normalization followed a similar method as described above where “equivalent” peptide samples (i.e., those from the same gel slice or “equivalent” peptide samples) from different replicates were compared with one another. For each protein or peptide common to all equivalent peptide
samples, the intensity in that sample relative to the average across all equivalent samples was calculated. The median of that relative intensity in each peptide sample was used to normalize all protein or peptide intensities from that sample. The final total protein or peptide intensity per replicate was calculated by the sum of all normalized intensities in samples derived from that replicate. It is important to note that peptide samples derived from SUMO1 and SUMO2 cells were considered equivalent for normalization purposes, which assumes largely similar abundances of proteins or peptides between cell types. Zero intensity values were replaced from log2-transformed data (Perseus default settings) and outliers were defined by 5% FDR from Student’s t-test using an S0 value of 0.1. A summary of these data can be found in supplemental File S3.

Bioinformatic Analysis of the SUMO Site Proteomics

In total, 429 proteins identified with at least one SUMO1 or SUMO2 modification site were uploaded to STRING (35) for network analysis. Only proteins associated by a minimum STRING interaction score of 0.7 (high confidence) were included in the final network. Disconnected nodes were removed. Selected groups of functionally related proteins were resubmitted to STRING create smaller subnetworks. These were visualized in Cytoscape v 3.7.2 (36) allowing the graphical display of numbers of sites identified and total GG-K peptide intensity into the protein networks. Net charge at pH 7.4 of sequences surrounding SUMO conjugation sites was predicted using 21 residue sequence windows input into the isoelectric point calculator tool (37). Profiles of charge distribution along full-length protein sequences were calculated on a sequence window basis for each amino acid. The net charge for sequence windows varying from 5 to 100 amino acids around each amino acid was calculated assuming a score of −1 for aspartic acid or glutamic acid residues and +1 for lysine or arginine. Consideration of histidine residues had little effect on overall profiles. For each amino acid, the 20 different net charge per window values were all plotted on the same charts as line graphs using amino acid residue number as the x-axis value and net window charge on the y-axis.

RNA Preparation and Real-time Quantitative PCR (RT-qPCR)

Total RNA was extracted using RNeasy Mini Kit (Qiagen) and treated with the on-column Rnase-Free DNase Set (Qiagen) according to the manufacturer’s instructions. RNA concentration was then measured using NanoDrop and 1 μg of total RNA per sample was subsequently used to perform a two-step reverse transcription polymerase chain reaction (RT-PCR) using random hexamers and First Strand cDNA Synthesis Kit (Thermo Fisher Scientific). Each qPCR reaction contained PerfeCTa SYBR Green FastMix ROX (Quantabio), forward and reverse primer mix (200 nM final concentration) and 6 ng of analyzed cDNA and was set up in triplicates in MicroAmp Fast Optical 96-Well or 384-Well Reaction Plates with Barcodes (Applied Biosystems). The sequences of primers used were as follows: NANOG (hNANOG_FOR624 ACAGGTGAGAAGAGCTTCC; hNANOG_REV722 GAGGCCTTGAGG; hNANOG_REV723 AGGCGAGA; hNANOG_REV724 ACAAGCGAGGATGCTTCC), TBP (hTBP_FOR896 TGTGCTCACCCAAAGATAT; hTBP_REV193 TCGTCTGCAGTGAGCCTT), OCT4A (hOCT4A_FOR825 CCCACACTGCAGCAGATCA and hOCT4A_REV1064 ACCACACTGGACCGACATCC), KLF4 (hKLF4_FOR1630 GGCCCAATTACCCATCCT; hKLF4_REV1706 GGCAGATGA CTTTCCTGTAAATG), TBP (hTBP_FOR896 TGTGCTCACCCACCAAA CAA; hTBP_REV193 TCGTCTGCAGTGAGCCTT), NAPO (hNAPO_REV614 AGGCGAGA; hNAPO_REV615 GTCGTCAGTT), and TBP (hTBP_FOR896 TGTGCTCACCCAAAGATAT; hTBP_REV193 TCGTCTGCAGTGAGCCTT). Data were collected using QuantStudio 6 Flex Real-Time PCR Instrument and analyzed using corresponding software (Applied Biosystems). Relative amounts of specifically amplified cDNA were calculated using TBP amplicons as normalizers.

Experimental Design and Statistical Rationale

All proteomics analyses used a label-free quantitation method employing either triplicate or quadruplicate cell cultures (biological replicates). Biological replicates were individual cell cultures grown and treated separately from one another but originally derived from a single cell line culture just prior to the experiment. For example, comparisons between different cell lines took individual large-scale cultures for each cell line and split the cells equally among replicate culture dishes. Once these had grown to appropriate levels of confluence, they were treated as described. Intensity data from multiple mass spectrometry runs of the same peptide sample (technical replicates) were normalized against other samples from the same mass spectrometry run and then quantitative data from identical peptide samples aggregated together by summation prior to statistical analyses. Protein or peptide outliers were determined by two-sample Student’s t-tests in pairwise comparisons. Specific FDR and S0 values for filtering are described for each experiment above.

RESULTS

Inhibition of SUMO Modification Leads to Decreased Expression of Pluripotency Markers in hiPSCs

The pluripotent state in hESCs and hiPSCs is controlled by a network of transcription factors and other chromatin-associated proteins that determine the chromatin environment of key genes (1). To test the potential role of SUMO modification in the maintenance of pluripotency in hiPSCs, we used ML792 (26) a potent and selective inhibitor of SUMO Activating Enzyme (SAE). This inhibitor has been reported to block proliferation of cancer cells, particularly those over-expressing Myc (26), but has not been evaluated in hiPSCs. To address the role of SUMO modification in hiPSCs, ChiP4 cells were treated with ML792 in a series of time-course and dose–response experiments. We determined that 400 nM ML792 was the lowest concentration that effectively reduced SUMO modification after 4 h treatment with minimal effects on cell viability (supplemental Fig. S1). We restricted our analyses to ML792 treatment times that did not exceed 48 h, such that the early effects of SUMO modification inhibition could be evaluated. Microscopic examination revealed that ML792 treatment caused morphological changes with the ChiP4 cells becoming larger and flatter (Fig. 1A, supplemental Fig. S2, A−C). The rate of proliferation was unchanged after 24 h but was slightly reduced after 48 h (Fig. 1B). DNA staining of the cells and analysis by flow cytometry indicated that the cell cycle distribution after 24 h was unaltered by ML792 treatment but after 48 h displayed an increased proportion of cells in G2 phase and cells with increased DNA content suggesting endoreplication or failed mitosis (Fig. 1C). Western blot analysis revealed a loss of high-molecular-weight SUMO1 and SUMO2 conjugates and concomitant increase in free SUMOs in ChiP4 cells (Fig. 1D). This is likely to be a consequence of the rapid removal of SUMO from modified proteins by SUMO-specific proteases (SENP), which can be also measured by calculating a nuclear/cytoplasmic ratio for

SUMO Targets in Human Induced Pluripotent Stem Cells

Mol Cell Proteomics (2021) 20 100164

ASBMB
SUMO Targets in Human Induced Pluripotent Stem Cells

Inhibition of SUMO modification leads to decreased expression of pluripotency markers in ChiPS4 cells. A, ChiPS4 cells were treated with SUMO E1 activating enzyme inhibitor ML792 (400 nM) or DMSO vehicle for the indicated time, fixed, and stained using DAPI and Cy3 Cellmask. Cells were further analyzed using high contents microscopy (scale bar = 100 μm). B, ChiPS4 cells were seeded at a standard density of 3 × 10^5 cells/cm^2 in triplicate and either DMSO or 400 nM ML792 treated for the indicated durations. Cells were harvested using Tryple Select and counted. Data are plotted as a mean (line) ± SEM of individual replicates (dots), n = 3. Statistical significance was calculated with t-tests corrected for multiple comparisons using Holm–Sidak’s method (*p < 0.05 significantly different from the corresponding DMSO control). C, cells were collected as in (B), fixed, stained with propidium iodide (PI), and analyzed by flow cytometry. Plots are representative of three independent experiments. D, crude cell extracts taken from cells incubated at the indicated time points with 400 nM ML792 were analyzed by Western blotting to determine conjugation levels of SUMO1, SUMO2/3 (rabbit), and abundance of key pluripotency markers NANOG, SOX2, KLF4, and OCT4. Anti-Actin and anti-lamin A/C western blots were used as loading controls. Asterisk (*) indicates free SUMO1 or SUMO2/3. E, cells were treated with ML792 and after the indicated time total RNA was extracted. mRNA levels of NANOG, OCT4, SOX2, and KLF4 were determined by quantitative PCR. Relative mRNA expression levels (normalized to TBP) were plotted as mean values ± SEM of four independent experiments. **p < 0.01; ***p < 0.001; ****p < 0.0001 significantly different from the corresponding value for untreated control (two-way ANOVA followed by Sidak’s multiple comparison test).

SUMO signal in high contents microscopy (supplemental Fig. S2E). Analysis of the protein levels of key pluripotency markers indicated that levels of KLF4 and NANOG were substantially reduced in response to ML792 treatment, whereas levels of SOX2 and OCT4 displayed only a marginal reduction (Fig. 1D, supplemental Fig. S2D). This appeared to be predominantly a consequence of reduced transcription as NANOG and KLF4 mRNA levels also reduce after ML792 treatment, while levels of OCT4 and SOX2 mRNA were not significantly changed (Fig. 1E).

Inhibition of SUMO Modification Induces Phenotypic Changes but not Large-scale Proteomic Changes in hiPSC

To further investigate the nature and causes of the observed morphological changes induced by the inhibition of SUMO modification, ChiPS4 cells were treated with ML792 for 48 h and analyzed by phenotypic screening using a cell painting assay (29) (Fig. 2A). Principle component analysis (PCA) indicated that there are clear differences between cells treated with ML792 for 48 h and untreated or vehicle (DMSO)-treated cells. The main differences were found to occur in the nuclear...
Fig. 2. Inhibition of SUMO modification causes morphological changes but does not trigger large-scale proteome changes in hiPSCs. A, cell painting analysis. ChIPS4 cells were treated with PBS, DMSO vehicle, or 400 nM ML792 for 48 h. Cells were then stained, fixed, and analyzed using high content microscopy. The experiment was performed three times with eight replicates per condition. Feature information extracted from Cell Painting analysis was focused on subcellular compartments most affected by ML792 treatment. Most variation between treatments and controls in principal component analysis was captured by PC1. Selected graphs represent quantitation of individual measures contributing to the difference observed in principal component analysis: area of nuclei; nuclei form factor (size and shape of nucleus); nuclei FITC texture correlation (size of nucleolar structures).

B, ChIPS4 cells were treated for 48 h with DMSO vehicle or 400 nM ML792, fixed, and stained with DAPI (blue), anti-SUMO1 or anti-SUMO2/3 (sheep) (red) and anti-NANOG or anti-NOP58 (green) antibodies. Immunofluorescence (IF) images were obtained using Leica SP8 confocal microscope and a 60× water lens. All images contain 25 μm scale bar.

C, crude extracts from hiPSCs treated in triplicate with ML792 for 24 h or 48 h or not (0 h) were analyzed by label-free proteomics and the change in protein abundance of detected pluripotency markers (n = 14) was calculated as % of 0 h intensity. Paired t test p values are indicated. Average reduction is 13.2% (24 h) and 25.7% (48 h).

D, scatter plot of Log2 24 h/0 h and Log2 48 h/0 h abundance change for the entire 4741 protein whole cell proteomic dataset. Extreme outliers are indicated. All identified core and linker histones are represented by colored markers others are in gray. Linker histones were identified by STRING analysis as a functionally related group of proteins that are significantly reduced in abundance at 48 h compared with 0 h. Core histone proteins are indicated for reference.
SUMO Targets in Human Induced Pluripotent Stem Cells

compartment (Fig. 2A). Feature extraction identified changes in the global size (Area of nuclei) and shape (Nuclei form factor) of the nucleus and the structure of the nucleolus (Nuclei: FITC texture correlation) (Fig. 2A, supplemental Fig. S2, C and E). These findings were validated using traditional immunofluorescence (IF) approaches (Fig. 2B, supplemental Fig. S2, D and E). Consistent with previously presented data, NANOG expression and the size and shape of the nucleus are both affected by ML792 treatment. NOP58 was used as a marker of the nucleolus, which undergoes a dramatic increase in size and shape (Fig. 2B, supplemental Fig. S2E). As expected, the classic punctate nuclear localization pattern of SUMO1 and SUMO2 is altered by their deconjugation from substrates, becoming more diffuse and less tightly associated with the nucleus (Fig. 2B, supplemental Fig. S2E).

To evaluate the effect of inhibition of SUMO modification on the global proteome in hiPSCs, total protein extracts were prepared from ChiPS4 cells either untreated or treated with ML792 for 24 or 48 h and analyzed by label-free quantitative proteomics. Data for 4741 proteins was obtained (supplemental File S1). Consistent with SUMO conjugation influencing the pluripotent state, known pluripotency markers were modestly but significantly reduced during 24 h and 48 h ML792 exposure (Fig. 2C). However, overall protein abundance changes compared at both time points showed little evidence for large-scale shifts (Fig. 2D), with very few functionally related proteins undergoing coordinated regulation according to STRING: Linker histones appeared to be reduced in abundance after 48 h, but not 24 h (Fig. 2D), and proteins from the gene ontology group “Collagen-associated extracellular matrix” had members both up- and downregulated (supplemental File S1). Alone these data do not appear to provide an obvious link between the morphological changes induced by SUMO inhibition and underlying protein abundance changes. Thus it is likely that the deSUMOylation of key regulators or the accumulation of multiple small protein abundance changes is responsible for the phenotypic consequences of ML792 treatment on hiPSCs.

Generation of hiPSC Lines for SUMO Proteomic Analysis

Our data suggest that SUMO influences the pluripotent state of hiPSCs. Given that previous studies of SUMOylation have typically focused on somatic cells, it was important to establish the SUMOylome of hiPSCs to identify candidate proteins that either directly or indirectly contribute to the observed phenotype. We adapted a proteomic approach that allows sites in proteins modified by SUMO1 and SUMO2/3 to be identified (38). To enable this analysis in hiPSCs, the ChiPS4 cell line was engineered to stably express 6His-SUMO-mCherry constructs for either SUMO1 or SUMO2 (Fig. 3, A and B) that incorporated the C-terminal TGG to KGG mutations to facilitate GlyGly-K peptide immunoprecipitation and identification as described previously (38). As mCherry is linked to the C-terminus of SUMO, the expressed fusion protein will be processed by endogenous SUMO proteases to expose the C-terminal GlyGly sequence for conjugation and release free mCherry. A representative single cell clone for each SUMO was selected based on the expression of free mCherry and the level of SUMO paralogue expression (Fig. 3C). Clones selected for SUMO site proteomic experiments were extensively characterized to ensure that the exogenous SUMO was functional and that the cells retained their pluripotency. Western blotting indicated that His-tagged SUMO-KGG paralogues were conjugated to substrates in response to heat shock (supplemental Fig. S3). Cells expressing SUMO1-KGG and SUMO2-KGG had normal cell cycle profiles (supplemental Fig. S4A), expressed levels of pluripotency markers comparable to wild-type ChiPS4 cells (supplemental Fig. S4, B and C), and retained the ability to differentiate into endoderm, ectoderm, and mesoderm (supplemental Fig. S4D). Analysis of the whole cell proteomes (Fig. 3D, supplemental File S2) of ChiPS4 cells expressing SUMO1-KGG and SUMO2-KGG identified the expected exogenous mCherry, SUMO1, and SUMO2 peptides (Fig. 3E) while peptides common to both endogenous and exogenous SUMOs showed that both types were conjugated to substrates at roughly similar levels (Fig. 3F). Importantly, the engineered cell lines did not show large-scale differences from parental cells in their expressed proteomes (Fig. 3, G and H, supplemental File S2). Together these data indicate that expression of SUMO mutants did not disrupt the normal pluripotent state or differentiation potential of ChiPS4 cells.

Identification of SUMO1 and SUMO2 Targets in hiPSCs

The workflow for the identification of SUMO1 and SUMO2 targets incorporates proteomic analysis at three levels (supplemental Fig. S5A). This involved analysis of whole cell extracts to monitor total protein levels, analysis of nickel affinity purified proteins to identify SUMO modified proteins, and analysis of GG-K immunoprecipitations to define sites of SUMO modification. SUMO1/SUMO2 comparisons can be made at the site level because after LysC digestion both mutants leave the same GG-K adduct on substrates (supplemental Fig. S5B), and so intensity comparisons can be used to infer preference for SUMO type at the site level. The experiment was conducted twice in triplicate and PCA indicated that replicates performed at the same time displayed a high degree of clustering (supplemental Fig. S5C). PCA also indicated clear differences between SUMO1 and SUMO2 as well as between experiments carried out at different times (supplemental Fig. S5C). This is likely to be a reflection of the precise growth state of the cells when the experiment was conducted. Very few total protein abundance differences between SUMO1 and SUMO2 cell were consistent to both experimental runs, but there were substantial and consistent differences between SUMO1 and SUMO2 at both nickel affinity purifications and at the site level (supplemental Fig. S5, D
SUMO Targets in Human Induced Pluripotent Stem Cells

Fig. 3. ChiPS4 cell lines engineered for SUMO1 and SUMO2 site proteomic analysis. A, overview of the principles behind the SUMO-mCherry construct design and the utility of the expressed proteins for SUMO site proteomic analysis in CHiPS4 cells. The C-terminal mCherry protein used for cell selection is cleaved away from 6His-SUMO by endogenous SUMO proteases allowing conjugation to substrate proteins. B, scheme representing the piggyBac construct design used for generation of CHiPS4 cell lines expressing 6His-SUMO1-KGG-mCherry or 6His-SUMO2-KGG-mCherry. C, flow cytometry analysis of single cell clones using mCherry expression levels to infer SUMO expression levels. D, coomassie-stained SDS-PAGE gel fractionating whole cell protein extracts from parental CHiPS4 cells (WT) and the selected 6His-SUMO-KGG-mCherry clones prepared in triplicate. This was used to monitor SUMO overexpression levels using proteomic analysis and each lane was excised into four sections allowing differentiation between conjugated (slices A–C) and unconjugated (Slice D) SUMO forms. E, peptide intensity data from slices A–D for two peptides each from 6His-SUMO1-KGG (left) and 6His-SUMO2-KGG (center) that are unique to the exogenous constructs. Data for 20 mCherry peptides are also shown (right). F, peptide intensity data from slices A–C for four peptides from SUMO1 (left) and three from SUMO2 (right) that are common to both the endogenous and exogenous forms of the proteins. G, quantitative data from 3863 proteins identified from the gel shown in (D) were compared by principal component analysis. H, numerical ratio and unpaired Student’s t test results comparing WT parental cells with 6His-SUMO1-KGG-mCherry cells (left), and WT with 6His-SUMO2-KGG-mCherry cells (right). Outliers (red markers) were defined in Perseus by 5% FDR with an S0 value of 0.1 (78 outliers from WT versus SUMO1 cells and 64 from WT versus SUMO2 cells). Gene names from extreme outliers are indicated.

and E). Across the two experimental runs (supplemental Fig. S5E) and aggregating the data for SUMO1 and SUMO2, a total of 976 SUMO sites were identified in 427 proteins. Approximately 84% of these had already been described in at least one of four large-scale SUMO2 and two SUMO1 site proteomics studies totalling 49,824 unique sites of non-stem-cell origin (Fig. 4A, supplemental File S3). DNA methyltransferase 3B (DNMT3B) and the key embryonic stem cell
transcription factor SALL4 were among a small group of proteins with at least three novel sites in this study (Fig. 4A). Although peptide intensity is a relatively imprecise proxy for abundance, it has been successfully used for SUMO-substrate branched peptides to separate high occupancy from low occupancy sites (39). For our data total GG-K peptide intensity suggests SALL4 is among the most abundantly modified substrates, while the methyl DNA binding protein MBD1 contains eight sites and is also in the top cohort of substrates by modified peptide intensity (Fig. 4B). Transcription intermediary factors 1α and 1β (TRIM24 and TRIM28) are also both highly modified substrates. The boundary and chromatin isolation factor CTCF is heavily modified with SUMO, consistent with a role for SUMO in chromatin architecture (Fig. 4B). There is also evidence for extensive SUMO chain formation as the branch points from
SUMO2/3 chains are among the most abundant GG-K peptides (Fig. 4B). Strikingly, the SUMOylated forms of a number of these nuclear substrates could be detected directly in total whole cell lysates from control hiPSC4 cells, but not in ML792-treated hiPSCs (Fig. 4C), implicating SUMO as a major regulator of the total pool of these proteins. SUMO modification of some of these proteins was confirmed by immunoprecipitation using target-specific antibodies followed by western blotting with either SUMO1 or SUMO2 antibodies (supplemental Fig. S6). STRING enrichment analysis of the 427 modified proteins created a network consisting of three broad clusters that could be categorized as having functions in ribosome biogenesis, RNA splicing, and regulation of gene expression (Fig. 4D). Despite forming extensive protein networks (supplemental Fig. S7, A and B), proteins involved in ribosome biogenesis and RNA splicing represented only approximately 5% of the total GGK peptide intensity (Fig. 4B) insert. Most of the remainder have roles in transcription and chromatin structure or are closely linked to these functions (supplemental Fig. S7, C–H). There is a prominent network of zinc-finger transcription factors, closely associated with TRIM28 (supplemental Fig. S7C), which contains many of the most heavily SUMOylated proteins identified. The TRIM-ZNF-SUMO axis may play a key role in silencing retroviral elements, and the TRIM-ZNF substrates such as GTF2I, SAFB2, and MGA (supplemental Fig. S7C) are among these proteins. Together these networks and clusters of proteins provide multiple direct and indirect links between SUMO and chromatin structure regulation.

### Differences between SUMO1 and SUMO2 at the Protein and Acceptor Site Level

The proteomic experimental design allowed quantitative comparisons between SUMO1 and SUMO2 at multiple stages of the purification process (supplemental Fig. S5A): SUMO1/SUMO2 ratios from crude hiPSC cell extracts show there to be few differences (0.03% significant) at the whole proteome level (Fig. 5A). There are also surprisingly few differences (7.8% significant) between NiNTA purifications from the two cell types (Fig. 5A). Exceptions include the well-documented SUMO1 substrate RanGAP1, along with TRIM24 and TRIM33, which all appear to show similar levels of SUMO1 preference (Fig. 5A). In contrast, over half of the GGK-containing peptides quantified in both experimental runs and both cell lines showed large and significant difference between SUMO1 and SUMO2 cells (Fig. 5A). Extreme examples of SUMO1 preferential sites include not only RanGAP1 K524, but also TRIM33 K776, NFRKB K359, PNN K157, TFTP K216, and two sites in TOP1 (K117 and K134) (Fig. 5A). Conversely, TRIM28 contains two of the most SUMO2-preferential sites at K507 and K779, and lysines 48 and 63 from ubiquitin also seem to be among the abundant SUMO2 acceptors (Fig. 5A). In the context of whole proteins, three key proteins in our dataset, SALL4, TRIM24, and TRIM33, show largely SUMO1 preferential modification, while TRIM28 and CTCF show apparent preference for SUMO2 (Fig. 5, B and C). This was broadly confirmed by Western blot analysis from NINTA purifications (Fig. 5D) and immunoprecipitation (supplemental Fig. S6), although in some cases the degree of preference was not as striking as expected. In particular, TRIM24 and TRIM28, which contained some of the most extreme SUMO paralogue-selective sites according to mass spectrometry, appeared by Western Blot of the whole proteins not to display strong SUMO paralogue preference. It is possible that some sites in these proteins that significantly influence overall modification were not detected by mass spectrometry and so skewed predictions of protein-level preference. It is important to note that although Western blot analysis of NINTA purifications confirmed the SUMO2-preferential modification of CTCF, both the modified and unmodified forms of CTCF were purified (Fig. 5D). Thus, it seems likely that large amounts of unmodified CTCF obscured the SUMO2 preference in the NINTA purification proteomic data. This effect may be rare, but highlights potential weaknesses in proteomics studies when using relatively low-stringency purifications such as 6His/Ni-NTA pull-downs.

### Preference for SUMO2 Modification in Regions of Higher Negative Charge

The proteomic data reveal many multiply modified proteins to have a strong overall SUMO paralogue selection. TOP1, TRIM33, ZNF462, and ZNF532 all contain multiple SUMO1-specific sites, and conversely, DNMT3a, CHD4, ubiquitin, and SUMOs 2 and 3 themselves have a majority of SUMO2-specific sites (supplemental Fig. S8). However, a number of substrates such as GTF2I, SAFB2, and MGA (supplemental Fig. S8) have a mixture of sites showing varied SUMO type preference. This broad range of site-specific SUMO paralogue preference raises the question of how specificity is determined. By averaging the SUMO1/SUMO2 peptide intensity ratio data over the two experimental runs, we ranked 739 sites by paralogue preference from SUMO1 to SUMO2 (Fig. 6A). Not all sites could be included for sequence analysis as sites close to protein N or C termini lacked amino acids in their sequence windows. Sequence logos of the top and bottom 123 sites (one-sixth of total) show broadly similar motifs for SUMO1 and SUMO2 sites (Fig. 6B), with both showing the characteristic ψKxE motif. However, outside the consensus SUMO2 sites are more prone to have D or E in the −2 position.
Fig. 5. Validation of SUMOylation status of abundant SUMO substrates in ChIPS4 cells. A, scatter plots of log2 SUMO1/SUMO2 ratio and $-\log_{10}$ Student's t test p-value for proteins or peptides detected in the different cellular fractions. Red markers were found to be significantly different in both experimental runs. Selected outliers are indicated. Numbers of significantly differing proteins or peptides compared with the entire set of proteins or peptides quantified are shown. B, schematic presentations of selected proteins found to have high total GG-K peptide intensities in the present study. Site positions are indicated by number. SUMO preference is represented by color and GGK peptide intensity by the size of the site node (see key). Site node border line thickness represents number of experiments in which it was found to show a significant difference. C, log2 SUMO1/SUMO2 ratio in selected proteins for different cellular fractions. D, ChIP-seq: WT, SUMO1-KGG, SUMO2-KGG; ML792, NINTA, INPUT; WB: anti-SALL4, anti-CTCF, anti-TRIM24, anti-TRIM28, anti-TRIM33.
than SUMO1 sites, and a significant number of SUMO1 sites have P in +3 (Fig. 6B). More generally, D/E residues are more enriched within the 21 residue sequence windows of SUMO2 than SUMO1. This is confirmed by sequence window charge analysis (Fig. 6C), which shows that acceptor lysine residues preferentially modified with SUMO2 over SUMO1 are more likely to be embedded in a sequence that is net negatively charged at pH7.4 than those showing SUMO1 preference. This trend is also generally progressive across the spectrum of site-specific SUMO parologue selection (supplemental Fig. S9). For some proteins where SUMO parologue preference varies in different regions of the sequence, this coincides with local charge variations consistent with SUMO2 preference in acidic domains. SALL4, CHD4, and SAFB (Fig. 6D) show that sites preferentially modified by SUMO2 were generally negatively charged while SUMO1-preferential modification took place in regions of the protein that were more positively charged.

DISCUSSION
Our studies indicate that SUMO influences the pluripotent state of hiPSCs. Using a potent and highly specific inhibitor of the E1 SUMO Activating Enzyme ML792 (26) we blocked de novo SUMO modification, which allowed endogenous SUMO specific proteases to remove SUMO from previously modified proteins. In this way, ML792 treatment effectively deSUMOylated cellular proteins. In response to 48 h of 400 nM ML792 exposure, ChIPS4 cells showed reduced level of pluripotency markers and underwent dramatic morphological changes, particularly to nuclear structure and size. Over the same period of time, there appeared to be few large-scale changes to the cellular proteome, implying that the consequences of loss of SUMOylation in hiPSCs primarily involve functional changes to factors critical for nuclear structure and function, probably followed by multiple modest protein abundance changes, which together lead to the observed phenotype. Candidates for these SUMOylated factors were identified by SUMO site proteomic analysis. The major network that accounted for the bulk of SUMO modification sites was associated with negative regulation of gene expression. At the heart of this network is TRIM28, the histone methyl transferase SETDB1 and the Chromobox silencer CBX3. ChIP-seq derived locations of TRIM28, SETDB1, and CBX3 indicate that they are associated with retroviral elements (41). These proteins along with SUMO have previously been shown to function in HERV silencing in mouse ES cells (40, 42) and adult human cells (43, 44) and this is consistent with our proteomic analysis that indicates that all three of these proteins are heavily SUMO modified (Fig. 4). The TRIM28 corepressor functions by interacting with DNA-bound Kruppel type Zinc finger proteins, and these proteins are also identified as being SUMO modified in our proteomic studies and are part of the large TRIM28 centric network of SUMO modified proteins. It is also suggested that a number of developmental genes are repressed by TRIM28/KRAB-ZNFs through H3K9me3 and de novo DNA methylation of their promoter regions (45), thus making TRIM28/ZNFs a crucial link in maintenance of pluripotency in human stem cells. These data are consistent with the wide distribution of SUMO on chromatin (46–49) and with a very different distribution in murine fibroblasts and ESCs (9). Recently Theurillat et al. (50) reported a SUMO site proteomic analysis of mouse ESCs. In this case the method used allowed analysis of endogenous SUMO2 but not SUMO1 modification sites. The number of sites identified by Theurillat et al. (49) was similar (608 SUMO2 sites in 350 proteins) to that reported here (976 SUMO1 plus SUMO2 sites in 427 proteins), as were the major functional networks. However, the precise targets identified were very different, with only SALL4 of the top 20 mouse ES cell specific proteins being present in the top 50 (based on peptide intensity) SUMO modified proteins in human stem cells reported here (Fig. 4B). Such differences presumably reflect the differences between mESCs and hiPSCs and the developmental stages that these cells represent. While the mouse cells were established from blastocysts, the human cells are derived by reprogramming normal somatic cells (25). In our study the analysis of SUMO1 and SUMO2 proteomes was facilitated by expression of exogenous versions of modified SUMOs. While expression levels of the exogenous SUMO were maintained at levels close to endogenous SUMO1 and SUMO2/3, this is by definition overexpression, and it is possible that this overexpression could influence the extent to which substrates and modification sites are conjugated to the different SUMO paralogues.

Analysis of the SUMO proteome of the ChIPS4 hiPSCs shows that well-defined groups of proteins are modified. Aside from the TRIM28/ZNF network mentioned above, proteins involved in “ribosome biogenesis” and “splicing” are SUMO modified, and this likely impacts on the normal growth and self-renewal of the hiPSCs. However, the largest network of proteins falls into the category of “negative regulation of transcription,” with many chromatin remodelers, chromatin modification, and DNA modification enzymes identified as SUMO substrates. Thus, SUMO modification is likely to play an important role in the control of pluripotency in hiPSCs by repressing genes that either disrupt pluripotency or drive differentiation.
SUMO Targets in Human Induced Pluripotent Stem Cells

**Fig. 6.** SUMO paralogue preference at the site level in hiPSCs is influenced by proximal acidic residues. A, Log$_2$ SUMO1/SUMO2 ratio versus rank of ratio for 738 GG-K containing peptides that could be numerically compared between SUMO1 and SUMO2 samples. Top and bottom 1/6th (123 sites) by ratio are selected to represent SUMO paralogue-preferential sites (colored) with the remainder marked in gray. B, plots Log$_2$ SUMO1/SUMO2 ratio versus rank of ratio for 738 GG-K containing peptides that could be numerically compared between SUMO1 and SUMO2 samples. Top and bottom 1/6th (123 sites) by ratio are selected to represent SUMO paralogue-preferential sites (colored) with the remainder marked in gray. C, comparison between SUMO1 and SUMO2-preferential sites for predicted net charge at pH7.4 of the amino acid region encompassing −10 to +10 residues around the acceptor lysine. Charge predicted using Isoelectric Point Calculator tool (37). D, schematic presentations summarizing site-specific SUMOylation data, and predicted sequence charge distribution for SALL4, CHD4, and SAFB2. Net charge at each amino acid position in the sequence was calculated for sequence windows of sizes from 5 to 100 residues as indicated in the key (see Experimental Procedures for details). SUMO conjugation sites and 21 residue sequence windows are shown (right).
During our analysis, we also found that a large proportion of modification sites displayed a clear preference for either SUMO1 or SUMO2, and that this seems to be influenced by the charge distribution around the acceptor lysine. Specifically, lysines within acidic domains are more likely to be modified by SUMO2 than SUMO1. While this is by no means a strict rule, these data suggest that site-level SUMO paralog selection is at least in part defined by the electrostatic environment of the acceptor lysine. Intriguingly, structures of Ubc9 in complex with either SUMO1 or SUMO2 (51) show significant charge deviation between the two paralogues close to the active site of the E2 enzyme (supplemental Fig. S10), potentially implicating the SUMO molecule itself in site selection. It is important to note, however, that in spite of the clear variety of site-level SUMO paralogue preference, most proteins display little overall SUMO preference when considering the total cellular pool together, meaning examples of entirely SUMO1 or SUMO2/3 modified proteins are probably rare. A notable exception is RanGAP1, which displays a very strong SUMO1 preference. This is a consequence of the SUMO1 modified form being resistant to SUMO protease mediated removal, whereas the SUMO2 modified form is susceptible to SUMO protease cleavage (52).

Understanding the differences between SUMO1 and SUMO2/3 in terms of site selectivity and downstream functional outcomes will likely be critical in gaining a full understanding of the role of SUMOylation in all higher eukaryotic cell types.

DATA AVAILABILITY

Data underlying all figures and Supplemental Figures are available in the source data files.

The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE (53) partner repository with the dataset identifiers; PXD025867 (Changes in total proteome of ChiPS4 cells during ML792 treatment), PXD023241 (Characterization of ChiPS4 cells stably expressing 6His-SUMO1-KGG-mCherry and 6His-SUMO2-KGG-mCherry) and PXD028050 (Identification of SUMO1 and SUMO2 modified proteins from ChiPS4 cells).

Supplemental data—This article contains supplemental data.

Acknowledgments—We would like to acknowledge the invaluable help from various facilities at the University of Dundee: Flow Cytometry and Cell Sorting, National Phenotypic Screening Centre, Dundee Imaging Facility, Human Pluripotent Stem Cell Facility.

Funding and additional information—This work was supported by an Investigator Award from Wellcome (217196/Z/19/Z) and a Program grant from Cancer Research UK (C434/A21747) to R. T. H. M. L. is part of the Ubi-Code European Training Network that received funding from the European Union Horizon 2020 research and innovation program under the Marie Curie grant agreement No. 765445. B. M. was supported by the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No. 704989.

Author contributions—R. T. H. conceptualization; M. H. T. data curation; M. L. E. B., B. M., M. H. T., L. D., and R. T. H. formal analysis; B. M. and M. L. methodology; L. D. supervision; B. M., R. T. H., M. H. T., and L. D. writing—original draft.

Abbreviations—The abbreviations used are: bFGF, basic fibroblast growth factor; ERV, endogenous retroviral element; ESCs, embryonic stem cells; FACS, fluorescence activated cell sorting; GGK, GlyGly-Lys branched peptide; HERV, human endogenous retroviral element; hESCs, human embryonic stem cells; hiPSCs, human induced pluripotent stem cells; LIF, leukemia inhibitory factor; mESCs, mouse embryonic stem cells; SMA, smooth muscle actin.

Received June 3, 2021, and in revised from, October 11, 2021 Published, MOLCELLPROPS Papers in Press, October 18, 2021, https://doi.org/10.1016/j.mcp.2021.100164

REFERENCES

1. Young, R. A. (2011) Control of the embryonic stem cell state. Cell 144, 940–954
2. Takahashi, K., Tanabe, K., Oghara, M., Narita, M., Mitsuhashi, S., and Yamanaka, S. (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131, 861–872
3. Takahashi, K., and Yamanaka, S. (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126, 663–676
4. Yu J, Vodyanik, M. A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frané, J. L., Tian, S., Nie, J., Jonsdottir, G. A., Ruotti, V., Stewart, R., Slukvin, I. I., and Thomson, J. A. (2007) Induced pluripotent stem cell lines derived from human somatic cells. Science 318, 1917–1920
5. Apostolou, E., and Hochedlinger, K. (2013) Chromatin dynamics during cellular reprogramming. Nature 502, 482–487
6. Vierbuchen, T., and Wernig, M. (2012) Molecular roadblocks for cellular reprogramming. Mol. Cell 47, 827–838
7. Borkent, M., Bennett, B. D., Lackford, B., Bar-Nur, O., Brumbaugh, J., Wang, L., Du, Y., Fargo, D. C., Apostolou, E., Che loufi, S., Maherali, N., Elledge, S. J., Hu, G., and Hochedlinger, K. (2016) A serial shRNA screen for roadblocks to reprogramming identifies the protein modifier SUMO2. Stem Cell Rep. 6, 704–716
8. Che loufi, S., Elling, U., Hopf garner, B., Jung, Y. L., Murn, J., Ninova, M., Hubmann, M., Badeaux, A. I., Huong, C., Tenen, D., Wesche, D. J., Abazova, N., Hogue, M., Tademir, N., Brumbaugh, J., et al. (2015) The histone chaperone CAF-1 safeguards somatic cell identity. Nature 528, 218–224
9. Cossec, J. C., Theurillat, I., Chica, C., Bua Aguin, S., Gaume, X., Andrieux, A., Ithuribe, A., Jouvin, G., Li, H., Bossis, G., Seeler, J. S., Torres-Padilla, M. E., and Dejean, A. (2018) SUMO safeguards somatic and pluripotent cell identities by enforcing distinct chromatin states. Cell Stem Cell 23, 742–757.e8
10. Hendriks, I. A., and Vertegeal, A. C. (2016) A comprehensive compilation of SUMO proteomics. Nat. Rev. Mol. Cell Biol. 17, 581–595
11. Mahajan, R., Delphin, C., Guan, T., Gerace, L., and Melchior, F. (1997) A small ubiquitin-related polypeptide involved in targeting RanGAP1 to nuclear pore complex protein RanBP2. Cell 88, 97–107
12. Hay, R. T. (2005) Sumo: A history of modification. Mol. Cell 18, 1–12
SUMO Targets in Human Induced Pluripotent Stem Cells

13. Flotho, A., and Melchior, F. (2013) Sumoylation: A regulatory protein modification in health and disease. Annu. Rev. Biochem. 82, 357–385

14. Rodriguez, M. S., Dargemont, C., and Hay, R. T. (2001) SUMO-1 conjugation in vivo requires both a consensus modification motif and nuclear targeting. J. Biol. Chem. 276, 12654–12659

15. Sampson, D. A., Wang, M., and Matusin, M. J. (2001) The small ubiquitin-like modifier-1 (SUMO-1) consensus sequence mediates Ubch9 binding and is essential for SUMO-1 modification. J. Biol. Chem. 276, 21664–21669

16. Tatham, M. H., Jaffray, E., Vaughan, O. A., Desterro, J. M., Botting, C. H., Naismith, J. H., and Hay, R. T. (2001) Polymeric chains of SUMO-2 and SUMO-3 are conjugated to protein substrates by SAE1/SAE2 and Ubch9. J. Biol. Chem. 276, 35398–35374

17. Song, J., Durrin, L. K., Wilkinson, T. A., Krontiris, T. G., and Chen, Y. (2004) Identification of a SUMO-binding motif that recognizes SUMO-modified proteins. Proc. Natl. Acad. Sci. U. S. A. 101, 14373–14378

18. Williams, R. L., Hilton, D. J., Pease, S., Willson, T. A., Stewart, C. L., Gearing, D. P., Wagner, E. F., Metcalf, D., Nicola, N. A., and Gough, N. M. (1998) Myeloid leukaemia inhibitory factor maintains the developmental potential of embryonic stem cells. Nature 336, 684–687

19. Ying, Q. L., Nichols, J., Chambers, I., and Smith, A. (2003) BMP induction of Id proteins suppresses differentiation and sustains embryonic stem cell self-renewal in collaboration with STAT3. Cell 115, 281–292

20. Humphrey, R. K., Beattie, G. M., Lopez, A. D., Bucay, N., King, C. C., Firpo, M. T., Rose-John, S., and Hayek, A. (2004) Maintenance of pluripotency in human embryonic stem cells is STAT3 independent. Stem Cells 22, 522–530

21. Xu, C., Rosler, E., Jiang, J., Lebkowski, J. S., Chen, X., Li, D. S., Li, R., Addicks, G. C., Glennon, C., Zwaika, T. P., and Thomson, J. A. (2002) BMP4 initiates human embryonic stem cell differentiation to trophoblast. Nat. Biotechnol. 20, 1261–1264

22. James, D., Levine, A. J., Besser, D., and Hemmati-Brivanlou, A. (2005) SUMO Targets in Human Induced Pluripotent Stem Cells

23. James, D., Levine, A. J., Besser, D., and Hemmati-Brivanlou, A. (2005) SUMO Targets in Human Induced Pluripotent Stem Cells

24. Xu, C., Rosler, E., Jiang, J., Lebkowski, J. S., Gold, J. D., O’Sullivan, C., Delavan-Boorsma, K., Mok, M., Bronstein, A., and Carpenter, M. K. (2005) Basic fibroblast growth factor supports undifferentiated human embryonic stem cell growth without conditioned medium. Stem Cells 23, 315–323

25. Rossant, J. (2015) Mouse and human blastocyst-derived stem cells: Vive les potential of embryonic stem cells. Nature 336, 684–687

26. Ying, Q. L., Nichols, J., Chambers, I., and Smith, A. (2003) BMP induction of Id proteins suppresses differentiation and sustains embryonic stem cell self-renewal in collaboration with STAT3. Cell 115, 281–292

27. James, D., Levine, A. J., Besser, D., and Hemmati-Brivanlou, A. (2005) SUMO Targets in Human Induced Pluripotent Stem Cells

28. Ludwig, T. E., Levenstein, M. E., Jiang, J., Lebkowski, J. S., Gold, J. D., O’Sullivan, C., Delavan-Boorsma, K., Mok, M., Bronstein, A., and Carpenter, M. K. (2005) Basic fibroblast growth factor supports undifferentiated human embryonic stem cell growth without conditioned medium. Stem Cells 23, 315–323

29. Xu, C., Rosler, E., Jiang, J., Lebkowski, J. S., Chen, X., Li, D. S., Li, R., Addicks, G. C., Glennon, C., Zwaika, T. P., and Thomson, J. A. (2002) BMP4 initiates human embryonic stem cell differentiation to trophoblast. Nat. Biotechnol. 20, 1261–1264

30. Rossant, J. (2015) Mouse and human blastocyst-derived stem cells: Vive les differences. Development 142, 9–12

31. He, X., Riceberg, J., Soucy, T., Koenig, E., Minissaie, J., Gallery, M., Bernard, H., Yang, X., Liao, H., Rabino, C., Shah, P., Xega, K., Yan, Z.-H., Sintchak, M., Bradley, J., et al. (2017) Probing the roles of SUMOylation in cancer cell biology using a selective SAE inhibitor. Nat. Chem. Biol. 13, 1164–1171

32. Tatham, M. H., Geoffroy, M. C., Shen, L., Plechanovova, A., Hattersley, N., Jaffray, E. G., Palivoja, J. J., and Hay, R. T. (2008) RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation. Nat. Cell Biol. 10, 536–546

33. Ludwig, T. E., Levenstein, M. E., Jones, J. M., Berggren, W. T., Mitchell, E. R., Frane, J. L., Crandall, L. J., Daigh, C. A., Conard, K. R., Piekarczyk, M. E., Barsky, J. R., van der Vlist, P., Linn, R., Feltkamp, T. W., Gellman, M. J., and Theurillat, I. (2016) Cell painting, a high-content image-based assay for morpho-mapping using multiplexed multiparametric flow cytometry. Stem Cell Rep. 9, 153–165

34. Tie, C. H., Fernandes, L., Conde, L., Robbez-Masson, L., Sumner, R. P., Peacock, T., Rodriguez-Plata, M. T., Mickute, G., Gifford, R., Towers, G. J., Herrero, J., and Rowe, H. M. (2018) KAP1 regulates endogenous retroviruses in adult cells and contributes to innate immune control. EMBO Rep. 19, e45000

35. Czembirek, K., S瘢drzczek, E., Gladych, M., Raman, A. T., Heyn, H., Mereu, E., Chlebowski, P., and Andrzejewskas, A., Sozanska, B., Samant, N., Fak, K., Auguscik, P., Kosinski, M., Wroblewska, J. P., Tomczak, K., Kulcenty, K., et al. (2017) TRIM28 and interacting KRAB-ZNFs control self-renewal of human pluripotent stem cells through epigenetic repression of Pro-differentiation genes. Stem Cell Rep. 9, 2065–2080

36. Neyret-Kahn, H., Benhamied, M., Ye, T., Le Gras, S., Cossec, J. C., Lapuquette, P., Bischof, O., Ouspenskaia, M., Dasso, M., Seeler, J., Davidson, I., and Dejean, A. (2013) Sumoylation at chromatin governs coordinated repression of a transcriptional program essential for cell growth and proliferation. Genome Res. 23, 1563–1579

37. Niskanen, E. A., Malinen, M., Sutinen, P., Toropainen, S., Paikkanoh, V., Vihervaara, A., Joutsen, J., Kaikkonen, M. U., Sistonen, L., and Palvimo, J. J. (2015) Global SUMOylation on active chromatin is an acute heat stress response restricting transcription. Genome Biol. 16, 153

38. Seifert, A., Schofield, P., Barton, G. J., and Hay, R. T. (2015) Proteotoxic stress reprograms the chromatin landscape of SUMO modification. Sci. Signal. 8, rs7

39. Liu, H. W., Zhang, J., Heine, G. F., Arora, M., Gulcin Ozer, H., and Parvin, J. D. (2012) Chromatin modification by SUMO-1 stimulates the promoters of translation machinery genes. Nucleic Acids Res. 40, 10172–10186

40. Theurillat, I., Hendriks, I. A., Cossec, J. C., Andrzejewski, A., Nielsen, M. L., and Dejean, A. (2020) Extensive SUMO modification of repressive chromatin factors distinguishes pluripotent from somatic cells. Cell Rep. 32, 108146
51. Gareau, J. R., Reverter, D., and Lima, C. D. (2012) Determinants of small ubiquitin-like modifier 1 (SUMO1) protein specificity, E3 ligase, and SUMO-RanGAP1 binding activities of nucleoporin RanBP2. *J. Biol. Chem.* **287**, 4740–4751.

52. Zhu, S., Goeres, J., Sixt, K. M., Bekes, M., Zhang, X. D., Salvesen, G. S., and Matunis, M. J. (2009) Protection from isopeptidase-mediated deconjugation regulates paralog-selective sumoylation of RanGAP1. *Mol. Cell* **33**, 570–580.

53. Perez-Riverol, Y., Csordas, A., Bai, J., Bernal-Llinares, M., Hewapathirana, S., Kundu, D. J., Inuganti, A., Griss, J., Mayer, G., Eisenacher, M., Perez, E., Uszkoreit, J., Pfeuffer, J., Sachsenberg, T., Yilmaz, S., *et al.* (2019) The PRIDE database and related tools and resources in 2019: Improving support for quantification data. *Nucleic Acids Res.* **47**, D442–D450.

54. O’Shea, J. P., Chou, M. F., Quader, S. A., Ryan, J. K., Church, G. M., and Schwartz, D. (2013) pLogo: a probabilistic approach to visualizing sequence motifs. *Nat. Methods* **10**, 1211–1212.